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Abstract
Background Pharmacokinetics (PK) are severely altered in critically ill patients due to changes in volume of distribution 
(Vd) and/or drug clearance (Cl). This affects the target attainment of antibiotics in critically ill children. We aimed to iden-
tify gaps in current knowledge and to compare published PK parameters and target attainment of antibiotics in critically ill 
children to healthy children and critically ill adults.
Methods Systematic literature search in PubMed, EMBASE and Web of Science. Articles were labelled as relevant when 
they included information on PK of antibiotics in critically ill, non-neonatal, pediatric patients. Extracted PK-parameters 
included Vd, Cl, (trough) concentrations, AUC, probability of target attainment, and elimination half-life.
Results 50 relevant articles were identified. Studies focusing on vancomycin were most prevalent (17/50). Other studies 
included data on penicillins, cephalosporins, carbapenems and aminoglycosides, but data on ceftriaxone, ceftazidime, peni-
cillin and metronidazole could not be found. Critically ill children generally show a higher Cl and larger Vd than healthy 
children and critically ill adults. Reduced target-attainment was described in critically ill children for multiple antibiotics, 
including amoxicillin, piperacillin, cefotaxime, vancomycin, gentamicin, teicoplanin, amikacin and daptomycin. 38/50 articles 
included information on both Vd and Cl, but a dosing advice was given in only 22 articles.
Conclusion The majority of studies focus on agents where TDM is applied, while other antibiotics lack data altogether. The 
larger Vd and higher Cl in critically ill children might warrant a higher dose or extended infusions of antibiotics in this patient 
population to increase target-attainment. Studies frequently fail to provide a dosing advice for this patient population, even 
if the necessary information is available. Our study shows gaps in current knowledge and encourages future researchers to 
provide dosing advice for special populations whenever possible.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 2-019-00813 -w) contains 
supplementary material, which is available to authorized users.
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Key Points 
This review provides a complete and comprehensive 
overview of all studies regarding pharmacokinetics and 
target attainment of all antibiotic agents in critically ill 
children.
Current knowledge gaps include several frequently used 
antibiotics, such as ceftriaxone, ceftazidime, penicillin, 
flucloxacillin and metronidazole that lack data altogether 
in this patient population.
This literature overview hopes to inspire researchers to 
close these gaps, not only by publishing pharmacokinetic 
data, but also by providing dosing guidance for imple-
mentation in the clinic, as this information is vital to 
optimize antibiotic treatment in this vulnerable popula-
tion.
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populations, such as critically ill children, can be simulated 
using PK data [12].
Knowledge of altered PK parameters and desired PD tar-
gets is essential to serve as the basis for the development of 
individualized starting dosing guidelines and further indi-
vidualized dose adjustments using therapeutic drug monitor-
ing (TDM). Multiple studies have shown that the application 
of TDM improves target attainment of antibiotic agents in 
critically ill patients [3, 13–16].
The aim of this systematic review is to summarize the 
reported PK data and target attainment of antibiotics in 
critically ill children, in relation data from non-critically ill 
children and/or critically ill adult patients. This may aid to 
identify gaps in current knowledge for future research, to 
optimize dosing guidelines and support TDM practice.
2  Methods
2.1  Search Strategy
We performed a systematic search in concordance with 
PRISMA guidelines in MEDLINE (using PubMed), 
EMBASE and Web of Science databases from 1900 to April 
2017. The PRISMA checklist is included as Supplemental 
Data File 1. Researchers were alerted to additional results for 
the search after April 2017 until May 15th 2019 by automatic 
e-mail alerts, and articles after this period were screened and 
selected in the same manner as articles in the original search. 
Duplicate articles within each database and between data-
bases were excluded by using EndNote and manual selec-
tion. The main research question was broken down into four 
domains (Pharmacokinetics, Antibiotics, Critically ill and 
Children). Keywords were allocated to these domains and as 
many synonyms for each keyword as possible were included 
in the search. Whenever possible, keywords were converted 
to corresponding MeSH-terms and/or subject headings. In 
the final search, both MeSH-terms, Subject Headings and 
keywords in the title and abstract were included. In order to 
include all antibiotic agents for the ‘Antibiotic’ domain in 
our search, we used the term “Anti-Bacterial Agents” [Phar-
macological Action] from the MeSH Database in combina-
tion with a free text search built with all the drug names and 
substance names linked to this MeSH-term [17]. Antiviral 
and antifungal therapies were left out of the scope of this 
systematic review. An overview of the final search strategy 
is depicted in Table 1 and a full list of antibiotic agents in 
Supplemental Data File 2.
2.2  Study Selection
The title and abstract of every result in the search were 
screened for eligibility by SH, ND and LO. A study was 
1 Introduction
Antibiotics make up the most common class of drugs pre-
scribed to hospitalized children, with roughly 50% of patients 
receiving an antibiotic agent during their hospital stay [1]. In 
critically ill children, the prophylactic and therapeutic use of 
intravenous antibiotics is even more prevalent [1].
Currently, critically ill children are generally started on 
the same (weight-corrected) dose of antibiotic therapy as 
their non-critically ill counterparts. As a consequence of 
altered pharmacokinetics (PK) due to critical illness there 
is a high likelihood that target concentrations, associated 
with optimal efficacy while minimizing toxicity, are not 
attained. In intensive care unit (ICU) patients, antibiotic 
concentrations are outside of the therapeutic window in up 
to 41% of adult patients [2] and even 95% in a critically ill 
pediatric ICU (PICU) population [3]. This non-target attain-
ment in critically ill patients is caused by pathophysiological 
changes in volume of distribution (Vd), protein binding and/
or drug clearance (Cl) [4–6]. Contrary to renal dysfunction, 
an increased renal clearance caused by hemodynamic altera-
tions during critical illness, described as augmented renal 
clearance (ARC), is reported in up to 65% of critically ill 
adults [7, 8] and children [9, 10].
In addition to these pathophysiological alterations, young 
children also show developmental changes in almost all pro-
cesses involved in drug disposition. Apart from differences 
in body composition, children also show maturation of drug 
metabolizing enzymes and glomerular filtration rate (GFR) 
in the first years of life [11]. Currently, most pediatric dos-
ing guidelines for children older than 1 month (e.g. British 
National Formulary for Children and Dutch Pediatric For-
mulary) only present a single body-weight based dose, not 
accounting for these developmental changes.
Whether these changes in drug disposition lead to non-
target attainment of antibiotics in patients obviously also 
depends on the pharmacodynamic (PD) interaction between 
antibiotic and micro-organism. The two main parameters in 
this interaction are the susceptibility of the micro-organism, 
defined as the minimum inhibitory concentration (MIC), 
and the kill-characteristic of the antibiotic [4]. Different 
classes of antibiotics have different kill-characteristics and 
can be divided in time-dependent, concentration depend-
ent and exposure dependent antibiotics [4]. When the kill-
characteristic of an antibiotic are known, PD targets can be 
established for these antibiotics. Common PD targets for 
time-dependent, concentration dependent and exposure 
dependent antibiotics are the time free drug concentrations 
are above the MIC at the site of infection (fT > MIC), peak 
concentration over MIC (Cmax/MIC) and area under the 
curve (AUC) over MIC (AUC/MIC), respectively. Subse-
quently, the probability of reaching these targets in special 
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labelled as eligible when it contained information on all 
four domains (Pharmacokinetics, Antibiotics, Critically 
ill and Children). Studies were labelled as ineligible when 
information on one or more domains was missing, when 
the study population consisted of only adults or neonates 
(< 1 month old), and/or when all patients were treated with 
renal replacement therapy or extracorporeal membrane 
oxygenation because of the direct influence on Vd and Cl 
depending on the extracorporeal circuit. Critical illness was 
based solely on the mention of ICU admission, regardless 
of disease severity scores, organ dysfunction or diagnoses of 
patients. This was done in order to best reflect the heterog-
enous PICU population and identify the impact of (critical) 
illness on their PK parameters. When the study population 
consisted of a mix of critically ill children and non-critically 
ill children, neonates or adults studies were only included 
when PK data of the critically ill children was reported sepa-
rately. Other exclusion criteria were non-English articles, 
conference abstracts, letters to the editor, no full-text avail-
ability, animal studies, in vitro studies and/or oral dosing. 
Review articles were also excluded but the references in 
these reviews were screened for additional relevant articles 
not identified by our search.
Overlapping articles were included and non-overlapping 
articles between the three reviewers were screened again 
by SH and SdW and included if labelled as eligible by both 
researchers.
2.3  Data Extraction
For each eligible article data was systematically extracted 
and all the extracted data was entered in a database using 
Microsoft Excel. The extracted data included type of anti-
biotic studied, study design, dose, sample size, type of 
population, disease severity based on validated clinical 
scores (PELOD, PIM, PRISM-scores or STAT categories), 
renal dysfunction and age of subjects. In addition, the PK-
analysis used in the article was studied, whether a (Pop)PK 
model was used, how many compartments were included in 
the model, studied co-variates on PK, what PK-parameters 
were found, and any additional findings of interest were 
noted. Lastly, when a dosing advice for critically ill children 
was provided, this was noted.
The PK-parameters of interest that were collected were 
Vd, Cl, trough (Cmin) and peak (Cmax) concentrations, 
AUC, half-life (t½) and elimination rate constant (k). All 
values of PK-parameters were normalized in order to ease 
comparability between different studies. Vd was normalized 
to liters/kilogram (l/kg) and Cl values to l/kg/h (l/kg/h). In 
case of allometric scaling or covariate contribution to one 
of these parameters, which is often seen in pharmacometric 
models, the covariate values of a mean/median study patient 
were used to normalize PK-parameter values.
PD parameters that were collected included the prob-
ability of target attainment (PTA), MIC and PD targets for 
time-dependent, concentration dependent and exposure 
dependent antibiotics: fT > MIC, AUC/MIC and Cmax/MIC, 
respectively.
3  Results
The literature search in PubMed, EMBASE and Web of Sci-
ence yielded 1742 articles. After the exclusion of duplicate 
articles within each database and between the 3 databases a 
total of 1313 articles were screened. From the screening pro-
cess a total of 70 articles were labelled as eligible (Fig. 1).
Table 1  Overview of final search strategy in PubMed with MeSH (Medical Subject Headings) terms and free text keywords for each of the four 
domains (Pharmacokinetics, Antibiotics, Critically ill, and Children)
Terms within each domain were combined with OR, all domains were combined with AND, as shown in the Electronic Supplementary Material
Pharmacokinetics Antibiotics Critically ill Children
MeSH terms
Pharmacokinetics [Mesh]
Pharmacokinetics [Subheading]
Monte Carlo Method [Mesh]
Drug Monitoring [Mesh]
Drug Dosage Calculations [Mesh]
MeSH-terms
Anti-Bacterial 
Agents [Phar-
macological 
Action]
Anti-Bacterial 
Agents [Mesh]
MeSH terms
Intensive Care Units [Mesh]
Critical Illness [Mesh]
Critical Care [Mesh]
MeSH terms
Adolescent [Mesh]
Child [Mesh]
Infant [Mesh]
Title/abstract
Peak concentration*, Trough concentra-
tion*, Area Under Curve, Therapeutic 
Equivalency, Tissue Distribution, 
Pharmacokinetic*, PopPK, Target-
attainment, Drug monitoring, TDM, 
Pharmacodynamic*, Dose calculation*, 
Drug dos*
Title/abstract
See Electronic 
Supplementary 
Material
Title/abstract
Severe ill, severe illn*, severely ill, PICU, 
PICUs, ICU, ICUs, Critical Care, Inten-
sive Care Unit*, serious illn*, serious 
ill, seriously ill, critical illn*, critical ill, 
critically ill*
Title/abstract
Child*, schoolchild*, infan*, 
adolescen*, pediatri*, paediatr*, 
boy, boys, boyhood, girl, girls, girl-
hood, youth, youths, baby, babies, 
toddler*, teen, teens, teenager*, 
postnat*, puberty, preschool*, 
suckling*, picu
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Twenty-three of the included articles did contain infor-
mation on the PK of antibiotic agents in a population of 
critically ill children but results were mixed with either adult 
data or non-critically ill data and therefore excluded. One 
article [18] was included from the references of included 
articles and/or reviews regarding the subject. Additionally, 
two articles that did not come up during the systematic 
review and were not mention in references of reviews were 
added after the peer-review process [19, 20]. Data-extraction 
was performed for 50 full-text articles with data on the PK 
of antibiotics in critically ill children. A complete list of all 
50 articles and extracted PK-data is presented in Table 2.
3.1  β‑Lactam Antibiotics
3.1.1  Penicillins
3.1.1.1 Amoxicillin and  Clavulanic Acid Both studies on 
amoxicillin PK included patients that were treated with 
amoxicillin combined with clavulanic acid as a β-lactamase 
inhibitor [21, 22]. Doses used in the studies ranged from a 
single dose of 50 mg/kg amoxicillin and 5 mg/kg clavulanic 
acid to 100 mg/kg/day of amoxicillin and 20 mg/kg clavu-
lanic acid every 6 h. Patient characteristics within these 2 
studies varied: Jones et  al. [22] studied 15 children with 
pneumonia, asthma or pyelonephritis who were slightly 
older than the 50 patients in the study by de Cock [21]. In 
addition, data on renal function were not reported by Jones, 
nor was there any information on disease severity. The 
study by De Cock et al. included a varied PICU population 
of which 44% received the combination for postoperative 
prophylaxis. Patients had a median (range) PRISM-score of 
6.5 (0–32) and median (range) PELOD score of 1 (0–31).
Median estimated Vd was 0.368 and 0.469 l/kg for amoxi-
cillin and 0.306 and 0.434 l/kg for clavulanic acid for the 
De Cock and Jones study, respectively. Cl of amoxicillin, 
normalized to l/kg/h, was comparable between both studies 
at 0.242 and 0.257 l/kg/h, whereas clavulanic acid Cl was 
slightly higher in the study by Jones et al. (0.256 l/kg/h) 
compared to 0.174 l/kg/h in the study by De Cock et al.
De Cock et al. estimated PK-parameters using popula-
tion PK (PopPK) modelling. They identified weight, post-
menstrual age, cystatin C based estimated GFR (eGFR) and 
vasopressor treatment as significant co-variates on either Vd 
and/or Cl of amoxicillin and clavulanic acid. Target attain-
ment, which was defined as fT > MIC of 40% against an MIC 
of 8 mg/l, was reported only for clavulanic acid for 3 differ-
ent dosing regimens, including dosing regimens of 25 mg/
kg every 4–12 h the authors based on the British National 
Formulary for Children and Samford Guide for Antibiotic 
Therapy. Target attainment was estimated at 48–96% for 
bolus infusions and 53–99% for extended infusions of 1 h. 
Target attainment for amoxicillin was not reported in exact 
numbers but was identified from figures. Target attainment 
of time above MIC of 8 mg/l ranged from 10 to 85% for 
three different dosing schemes using bolus injections in 
children with no vasopressors and no renal dysfunction. 
Fig. 1  A total of 1742 articles 
were screened from the 3 
databases. After excluding 
duplicates and non-eligible arti-
cles and including articles from 
references a total of 48 eligible 
articles were analyzed for data 
extraction. RRT renal replace-
ment therapy, ECMO extracor-
poreal membrane oxygenation, 
ICU intensive care unit
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n C
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 C
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l/m
in
 
pe
r 1
.7 
m
2  ±
 13
8.0
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eig
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 fT
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m
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 (m
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o C
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 m
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eig
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e c
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: C
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e c
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m
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, d
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y
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 d–
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s
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eig
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m
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ica
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r m
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ra
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 0.
16
7 L
L/
kg
/h
Ce
nt
ra
l V
d =
 0.
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s c
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d d
os
e r
eg
i-
m
en
 of
 40
 m
g/
kg
, 
30
 m
in
 be
fo
re
 in
ci-
sio
n;
 20
 m
g/
kg
, a
t 
sta
rt 
of
 C
PB
; 2
0 m
g/
kg
, a
t t
he
 st
ar
t o
f 
re
wa
rm
in
g o
n C
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e m
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t o
f 
CP
B 
an
d a
t s
tar
t 
of
 re
wa
rm
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ra
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eig
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r o
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 re
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d c
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0.5
 =
 m
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d f
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t d
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3 d
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 m
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/d
ay
) i
n 
4 d
os
es
Co
ho
rt
7
M
RS
A
7 y
 (1
 m
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ra
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 C
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ra
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d f
ra
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l p
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4 d
os
es
, i
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 m
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 kg
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y o
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3 g
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l g
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ba
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pa
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a v
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y s
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nt
ro
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l 0
.55
 l/
kg
/h
 
(0
.10
–0
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l 0
.48
 
(0
.26
–1
.96
), 
an
d v
er
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: c
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ely
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9.6
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s f
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 d
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4.7
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8.9
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e
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l ±
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 m
g/
l ±
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3.6
7 h
 ±
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, V
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.06
 l/
kg
 ±
 1.
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, 
Cl
 0.
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 l/
kg
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 ±
 1.
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 0-t
au
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m
g/
l/h
 ±
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g/
l ±
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l ±
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 ±
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, V
d 1
.44
 l/
kg
 ±
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kg
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m
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Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: Systematic Review
Ta
bl
e 
2 
 (c
on
tin
ue
d)
Au
th
or
 
(y
ea
r) 
[c
ita
tio
n]
An
tib
io
tic
Do
se
St
ud
y 
de
sig
n
N
Ty
pe
 of
 
ill
ne
ss
Ag
e a
nd
 w
eig
ht
 
m
ea
n (
ra
ng
e)
AK
I 
in
clu
de
d?
Co
va
ria
tes
PK
 pa
ra
m
ete
rs
PT
A
Do
se
 ad
vi
ce
Ak
in
s 
(2
00
6)
 
[6
7]
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e
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rt
1
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.3 
kg
No
Re
na
l f
un
cti
on
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alb
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, b
lo
od
 
pr
es
su
re
, r
es
pi
-
ra
tio
n r
ate
, t
em
-
pe
ra
tu
re
, s
ex
El
im
in
ati
on
 ra
te 
co
ns
tan
t 0
.30
1/
h 
af
ter
 si
ng
le 
do
se
, 0
.15
1 i
n s
tea
dy
 
sta
te
Cm
ax
: 8
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 µg
/m
l a
fte
r s
in
gl
e d
os
e, 
Cm
in
: 0
.07
 µg
/m
l a
fte
r s
in
gl
e 
do
se
, 2
.7 
in
 st
ea
dy
 st
ate
t½
: 2
.31
 h 
af
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 si
ng
le 
do
se
, 4
.58
 in
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y s
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e
Vd
: 0
.06
7 l
/k
g a
fte
r s
in
gl
e d
os
e, 
0.0
89
 in
 st
ea
dy
 st
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: 2
0.1
3 m
l/k
g/
h a
fte
r s
in
gl
e d
os
e, 
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.47
 in
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ea
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l a
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e d
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e, 
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3.9
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ul
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1 d
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Co
ho
rt
4
M
ixe
d
9.7
5 y
 (8
–1
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)
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.5 
kg
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 kg
)
No
No
ne
Da
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:
M
ed
ian
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l: 
0.0
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2 l
/k
g/
h
M
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ian
 V
d:
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5 l
/k
g
M
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ian
 A
UC
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 m
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 C
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 C
m
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 C
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d d
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e C
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l b
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l f
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d p
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 C
m
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d. 
In
fu
sio
n 
in
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ho
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 ±
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(ra
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ot
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Ge
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am
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4 l
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n C
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0
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g i
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er
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1 p
ati
en
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0 p
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7 p
ati
en
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m
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ati
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ed
ict
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ra
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 of
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Cm
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 1 
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l
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e d
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ra
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se
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e s
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 of
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/d
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/d
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Ge
nt
am
ici
n
8 m
g/
kg
 ev
er
y 
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6 h
 in
fu
se
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in
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 m
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Co
ho
rt
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M
ixe
d
5.3
 m
o (
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–1
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y)
7.9
 kg
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QR
 
4.6
–1
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)
Ye
s
W
eig
ht
, a
ge
, C
lcr
Ge
nt
am
ici
n C
l 2
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 l/
h/
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 kg
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0.1
4 l
/h
/k
g
Di
str
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ut
io
na
l C
l 0
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 l/
h
Vd
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nt
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l c
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pa
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en
t 0
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kg
Vd
 pe
rip
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ra
l c
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pa
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en
t 3
.78
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r C
m
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IC
 8 
fo
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 2 
m
g/
l f
or
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e g
ro
up
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an
d d
os
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: P
TA
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% 
fo
r a
ll 
no
n-
ne
on
ate
s 
wi
th
 7 
m
g/
kg
 an
d 
PT
A 
10
0%
 fo
r a
ll 
ag
e g
ro
up
s w
ith
 
8 m
g/
kg
8 m
g/
kg
/d
os
e f
or
 
all
 ag
e g
ro
up
s. 
Do
sin
g i
nt
er
va
l 
de
pe
nd
en
t o
n a
ge
Za
ko
va
 
(2
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4)
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nt
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n
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n
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0
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d
0.3
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o (
0 d
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1 
m
o)
4.5
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g (
ra
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e 
no
t g
ive
n)
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s
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e, 
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ht
, 
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ica
tio
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PR
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M
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e, 
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ea
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in
e, 
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um
in
,
M
ed
ian
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d 0
.39
 l/
kg
 (I
QR
 
0.3
0–
0.5
0)
,
M
ed
ian
 el
im
in
ati
on
 ra
te 
co
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tan
t (
k)
 
0.1
8/
h (
IQ
R 
0.1
1–
0.2
4)
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.4%
 of
 pa
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wi
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 C
m
ax
 
tar
ge
t o
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6–
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g/
l 
(3
8.8
% 
be
lo
w,
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.8%
 
ab
ov
e)
22
.4%
 of
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tie
nt
 
wi
th
in
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 ta
rg
et 
of
 70
–1
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 m
g/
h/
l 
(3
7.3
% 
be
lo
w,
 40
.3%
 
ab
ov
e)
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.7%
 of
 pa
tie
nt
s 
wi
th
in
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-fr
ee
 
in
ter
va
l t
ar
ge
t o
f 
4–
16
 h 
(6
% 
be
lo
w,
 
40
.3%
 ab
ov
e)
6 m
g/
kg
/d
ay
 
in
 1 
do
se
 fo
r 
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tie
nt
s >
 5 
kg
 
an
d w
ith
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ti-
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e a
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[3
1]
Ge
nt
am
ici
n, 
ce
faz
ol
in
e
Ce
faz
ol
in
e: 
lo
ad
in
g 
do
se
 of
 40
 m
g/
kg
 at
 in
du
cti
on
 
of
 an
es
th
es
ia 
an
d 
10
5 m
g/
kg
/d
ay
 in
 
3 d
os
es
 fo
r 4
8 h
Ge
nt
am
ici
n l
oa
di
ng
 
do
se
 of
 5 
m
g/
kg
 
at 
in
du
cti
on
 of
 
an
es
th
es
ia 
an
d 
4 m
g/
kg
/d
ay
 fo
r 
48
 h
Co
ho
rt
19
Ca
rd
iac
 
su
rg
er
y
9.8
 m
o (
1 d
–2
.6 
y)
6.4
3 k
g 
(3
.8–
10
.5 
kg
)
No
No
ne
Ce
faz
ol
in
:
Pl
as
m
a c
on
ce
nt
ra
tio
n a
t e
nd
 of
 
su
rg
er
y 5
4 µ
g/
m
l ±
 16
, fi
rst
 C
m
in
 
12
 µg
/m
l ±
 7,
 st
ea
dy
-st
ate
 C
m
in
 
15
 µg
/m
l ±
 10
, s
tea
dy
-st
ate
 C
m
ax
 
19
 µg
/m
l ±
 22
Vd
: b
efo
re
 by
pa
ss
 pa
tie
nt
s 0
.19
1 l
/
kg
 ±
 0.
02
8, 
du
rin
g b
yp
as
s 0
.35
7 l
/
kg
 ±
 0.
09
6, 
af
ter
 by
pa
ss
 0.
12
7 l
/
kg
 ±
 0.
00
4 
K
 =
 be
fo
re
 by
pa
ss
 0.
73
8 ±
 0.
42
2, 
du
rin
g b
yp
as
s 0
.33
1 ±
 0.
22
6, 
af
ter
 
by
pa
ss
 1.
42
9 ±
 0.
47
0
Ge
nt
am
ici
n:
Cm
ax
 du
rin
g s
ur
ge
ry
 20
.8 
µg
/
m
l ±
 9.
5, 
m
ea
n c
on
ce
nt
ra
tio
ns
 at
 
th
e e
nd
 of
 su
rg
er
y 5
.9 
µg
/m
l ±
 1.
5. 
Fi
rst
 C
m
in
 1.
1 µ
g/
m
l ±
 0.
5, 
ste
ad
y-
sta
te 
Cm
in
 0.
8 µ
g/
m
l ±
 0.
9, 
ste
ad
y-
sta
te 
Cm
ax
 3.
2 µ
g/
m
l ±
 1.
2
Vd
 be
fo
re
 by
pa
ss
 0.
23
7 l
/k
g ±
 0.
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4, 
du
rin
g b
yp
as
s 0
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0 l
/k
g ±
 0.
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8, 
af
ter
 by
pa
ss
 0.
62
4 l
/k
g ±
 0.
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6 
K
 =
 be
fo
re
 by
pa
ss
 0.
96
2 ±
 0.
40
2, 
du
rin
g b
yp
as
s 0
.33
6 ±
 0.
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4, 
af
ter
 
by
pa
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18
8 ±
 0.
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9
No
t g
ive
n
Gi
an
no
ni
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6)
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4 d
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, C
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ate
, 
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nt
ra
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pr
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re
Te
rm
in
al 
t½
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 do
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2 h
 ±
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Te
rm
in
al 
t½
 in
 st
ea
dy
 st
ate
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1.3
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 ±
 0.
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Cl
 af
ter
 fi
rst
 do
se
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.27
 l/
kg
/h
 ±
 0.
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Cl
 in
 st
ea
dy
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ate
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 l/
kg
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 ±
 0.
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Vd
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 l/
kg
 ±
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 0.
1
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 in
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 ±
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T >
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eig
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 C
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a c
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m
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d C
SF
No
t g
ive
n
Ci
es
 
(2
01
7)
 
[3
5]
M
er
op
en
em
Ra
ng
e o
f d
iff
er-
en
t d
os
es
 fr
om
 
40
 m
g/
kg
/d
ay
 
to
 16
0 m
g/
kg
/
da
y o
ve
r 2
–4
 
do
se
s, 
in
fu
sio
n i
n 
30
 m
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1 p
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)
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W
eig
ht
, a
ge
, C
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 C
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 fT
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s c
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n d
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m
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atr
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na
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d 
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 do
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g 
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co
m
m
en
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 m
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4.1
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(4
 d–
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 y)
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 (2
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g)
Ye
s
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rg
et:
 fT
 >
 M
IC
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fT
 >
 4–
6 ×
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IC
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an
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T >
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IC
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K 
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ra
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rs 
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 co
nc
en
tra
tio
ns
 an
d P
D 
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ra
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ra
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6]
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til
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ici
n
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kg
 1 
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-
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n i
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 m
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r r
en
al 
in
su
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-
cie
nc
y, 
re
du
cti
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of
 do
sa
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pe
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ed
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th
er
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 ex
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sio
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sin
g i
nt
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va
l t
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2 h
 an
d/
or
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du
cti
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se
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3.0
 m
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kg
Co
ho
rt
9
M
ixe
d
4.6
 y 
(1
 
m
o–
15
.5 
y)
20
 kg
 
(3
.4–
70
 kg
)
No
Ag
e
Cm
ax
 33
 µm
ol
/l 
(ra
ng
e 2
3–
41
), 
Cm
in
 1.
3 µ
m
ol
/l 
(ra
ng
e 0
.2–
3.2
)
No
t g
ive
n
Be
ra
ng
er
 
(2
01
8)
 
[2
6]
Pi
pe
ra
cil
-
lin
 +
 ta
zo
-
ba
cta
m
Pi
pe
ra
cil
lin
 
35
0 m
g/
kg
/d
ay
 
in
 4 
do
se
s, 
in
fu
-
sio
n i
n 3
0 m
in
. 
Ta
zo
ba
cta
m
 
37
.5 
m
g/
kg
/d
ay
 in
 
4 d
os
es
, i
nf
us
io
n 
in
 30
 m
in
Co
ho
rt
67
M
ixe
d
2.3
–2
.6 
y (
1–
18
 
y)
11
.9–
13
.7 
kg
 
(2
.7–
53
)
Ye
s (
1 
pa
tie
nt
)
W
eig
ht
, e
GF
R,
 
PE
LO
D 
sc
or
e,
Pi
pe
ra
cil
lin
 t½
 m
ed
ian
 0.
9 h
 (r
an
ge
 
0.1
5–
4.2
 h)
Po
pu
lat
io
n p
ip
er
ac
ill
in
 C
l 0
.18
 l/
/
kg
/h
Po
pu
lat
io
n p
ip
er
ac
ill
in
 V
d 0
.35
1 
l/k
g
M
ed
ian
 (r
an
ge
) o
f 
tim
e >
 M
IC
 53
.3%
 
(0
–1
00
) a
nd
 4 
× 
M
IC
 
18
.3%
 (0
–1
00
). 
Ta
r-
ge
t M
IC
 no
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8 c
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r c
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 fT
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, f
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ra
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ra
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5.6
 m
g/
kg
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d
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)
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s
W
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Vd
 (c
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l c
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pa
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11
), 
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9 l
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g/
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0.1
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)
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ra
ng
es
 0.
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eig
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, C
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 C
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.08
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 ×
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eig
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 l
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cta
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 C
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  ×
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5 ×
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eig
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 >
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r m
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ra
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n
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-
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cta
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/d
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d
2.8
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 m
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.4–
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)
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W
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ra
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e, 
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 re
as
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tio
n
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ra
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lin
 C
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lin
 V
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13
 l/
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2 
0.1
1 l
/k
g
Ta
zo
ba
cta
m
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m
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 0.
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 l/
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0.1
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g
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h w
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sio
n i
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an
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/d
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. 
Ta
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et-
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m
en
t i
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fT
 >
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M
IC
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 m
g/
l
6 d
d 7
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0 m
g/
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/
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ol
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f c
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Lo
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g d
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n 1
 h
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gr
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 m
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 1 
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 m
g/
kg
 1 
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 m
ain
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do
se
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us
ed
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 1 
h
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M
ixe
d
3.1
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(4
 m
o–
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y)
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 kg
 (4
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8 k
g)
No
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e, 
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ig
ht
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C 3
5-
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t (
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 th
e 3
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g d
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es
) 
11
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 m
g/
h/
l ±
 41
0. 
Fo
r c
hi
l-
dr
en
 <
 12
 m
o (
n =
 4)
 14
84
 ±
 31
5 
an
d c
hi
ld
re
n >
 12
 m
o (
n =
 16
) 
11
21
 ±
 40
6
Cm
ax
 59
.9 
m
g/
l ±
 18
.8 
fo
r t
ot
al 
co
ho
rt,
 fo
r c
hi
ld
re
n <
 12
 m
o 
(n
 =
 4)
 71
.8 
m
g/
l ±
 9.
3 a
nd
 >
 12
 
m
o (
n =
 16
) 5
6.9
 ±
 9.
5
Cm
in
 9.
01
 m
g/
l ±
 4.
3 f
or
 to
tal
 
co
ho
rt,
 fo
r c
hi
ld
re
n <
 12
 m
o 
(n
 =
 4)
 12
.1 
m
g/
l ±
 4.
6 a
nd
 >
 12
 
m
o (
n =
 16
) 8
.24
 ±
 4
M
od
el 
pa
ra
m
ete
rs:
Cl
 0.
23
 l/
h, 
Vd
 3.
16
 L
, V
2 4
.7 
L,
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0.3
2 l
/h
, t
1/
2 a
lfa
 2.
0 h
, t
½ 
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ta 
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.3 
h, 
t½
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nt
ra
l c
om
pa
rtm
en
t 
9.5
 h
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pP
K 
m
od
el 
we
ig
ht
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rre
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 0.
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7 l
/k
g/
h, 
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0.2
6 l
/k
g
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K 
m
od
el 
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e c
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re
cte
d:
> 
12
 m
o:
 C
l 0
.26
 l/
h, 
Vd
 4.
17
 l
< 
12
 m
o:
 C
l 0
.04
 l/
h, 
Vd
 1.
43
 l
Su
bt
he
ra
pe
ut
ic 
Cm
in
 
m
or
e f
re
qu
en
t i
n 
ch
ild
re
n >
 12
 m
o 
(3
5%
) v
s. 
ch
il-
dr
en
 <
 12
 m
o (
8%
)
Si
m
ul
ati
on
 w
ith
 lo
ad
-
in
g d
os
e o
f 5
 m
g/
kg
 w
ith
 4 
m
g/
kg
/d
ay
 
m
ain
ten
an
ce
 do
se
 
fo
r c
hi
ld
re
n <
 12
 m
o 
an
d l
oa
di
ng
 do
se
 of
 
10
 m
g/
kg
 an
d 8
 m
g/
kg
/d
ay
 m
ain
ten
an
ce
 
do
se
 fo
r c
hi
l-
dr
en
 >
 12
 m
o g
av
e 
PT
A 
> 
90
%
Lo
ad
in
g d
os
e o
f 
5 m
g/
kg
 w
ith
 
4 m
g/
kg
 1 
dd
 
m
ain
ten
an
ce
 do
se
 
fo
r c
hi
ld
re
n <
 12
 
m
o
Lo
ad
in
g d
os
e o
f 
10
 m
g/
kg
 an
d 
8 m
g/
kg
 1 
dd
 
m
ain
ten
an
ce
 do
se
 
fo
r c
hi
ld
re
n >
 12
 
m
o
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se
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N
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pe
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ne
ss
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e a
nd
 w
eig
ht
 
m
ea
n (
ra
ng
e)
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clu
de
d?
Co
va
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 pa
ra
m
ete
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A
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se
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vi
ce
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(1
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[1
8]
Te
ico
pl
an
in
6 m
g/
kg
/d
ay
 in
 1 
do
se
 in
fu
sio
n i
n 
20
–3
0 m
in
Co
ho
rt
12
M
os
tly
 
ca
rd
iac
 
su
rg
er
y, 
1 p
ati
en
t 
he
ad
 
su
rg
er
y
6 y
 (2
.4–
11
.4 
y)
21
.4 
kg
 
(9
.3–
43
.5 
kg
)
No
No
ne
Af
ter
 fi
rst
 do
se
:
Vd
 0.
46
 l/
kg
 ±
 0.
04
 (V
c 0
.09
, V
2 
0.0
4, 
an
d V
3 0
.33
)
To
tal
 C
l 2
.38
 l/
kg
/h
 (r
en
al 
Cl
 1.
09
 
l/k
g/
h)
Te
rm
in
al 
t½
 11
.3 
h ±
 1.
0
Cm
in
 af
ter
 fi
rst
 do
se
: 1
.8 
m
g/
l ±
 0.
6
Cm
ax
 af
ter
 fi
rst
 do
se
: 
39
.3 
m
g/
l ±
 7.
6
Af
ter
 5t
h d
os
e:
Vd
 0.
56
 l/
kg
 ±
 0.
09
 (V
c 0
.09
, V
2 
0.0
8, 
an
d V
3 0
.4)
To
tal
 C
l 2
.19
 l/
kg
/h
 (r
en
al 
Cl
 no
t 
de
ter
m
in
ed
)
Te
rm
in
al 
t½
 16
.1 
h ±
 3.
4
Cm
in
 af
ter
 fi
fth
 do
se
: 3
.1 
m
g/
l ±
 1.
2
Cm
ax
 af
ter
 fi
fth
 do
se
: 
40
.8 
m
g/
l ±
 7.
4
–
8 m
g/
kg
 ev
er
y 1
2 h
 
sh
ou
ld
 be
 eff
ec
tiv
e 
to
 ac
hi
ev
e C
m
in
 
co
nc
en
tra
tio
ns
 of
 
11
 m
g/
l w
ith
in
 
48
 h.
 H
ig
he
r d
os
es
 
(e
.g.
 15
 m
g/
kg
 
ev
er
y 1
2 h
) m
ay
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ed
ed
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r t
he
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atm
en
t o
f b
ac
te-
ria
l e
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ar
di
tis
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nc
he
z 
(1
99
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9]
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ico
pl
an
in
Lo
ad
in
g d
os
e: 
3 
do
se
s o
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0 m
g/
kg
 ev
er
y 1
2 h
M
ain
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an
ce
 do
se
: 
10
 m
g/
kg
 ev
er
y 
24
 h
Co
ho
rt
21
Ca
rd
iac
Un
kn
ow
n (
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d–
12
 y)
W
eig
ht
 no
t 
gi
ve
n
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s
Ag
e
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C 
22
4.5
 m
g/
l/h
, V
 ce
nt
ra
l c
om
-
pa
rtm
en
t 0
.38
 l/
kg
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d a
t s
tea
dy
 
sta
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1.0
2 l
/k
g, 
Cl
 45
 m
l/k
g/
h, 
Cm
ax
 26
.2 
m
g/
l, 
Cm
in
 st
ea
dy
 
sta
te 
5.8
 m
g/
l, 
t½
 17
.41
 h
PT
A:
 60
% 
of
 sa
m
pl
es
 
we
re
 ab
ov
e 5
 m
g/
l, 
25
% 
of
 sa
m
pl
es
 
ab
ov
e 1
0 m
g/
l. 
On
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 11
% 
of
 
Cm
in
 co
nc
en
tra
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tio
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 >
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 m
g/
l.
No
 di
ffe
re
nc
es
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n-
ce
nt
ra
tio
ns
 an
d P
K 
pa
ra
m
ete
rs 
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ee
n 
di
ffe
re
nt
 ag
e g
ro
up
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m
o, 
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 m
o, 
an
d >
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 m
o)
No
t g
ive
n
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ed
is-
sia
n 
(2
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7)
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2]
Va
nc
om
yc
in
M
ed
ian
 45
 m
g/
kg
/d
ay
 (I
QR
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.0–
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.6 
m
g/
kg
/d
ay
)
Co
ho
rt
25
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M
ixe
d
9.8
 y 
(u
nk
no
wn
)
30
.0 
kg
 (I
QR
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.0–
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.0)
No
AR
C 
(C
lva
-
nc
o >
 13
0 m
l/
m
in
), 
ag
e, 
we
ig
ht
, s
ex
, 
se
ru
m
 cr
ea
ti-
ni
ne
Va
nc
om
yc
in
 V
d o
ve
ra
ll 
0.6
2 l
/k
g 
(0
.58
–0
.66
)
Va
nc
om
yc
in
 t½
 3.
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 h 
(IQ
R 
3.0
6–
4.5
1)
Va
nc
om
yc
in
 C
l 9
7.3
4 m
l/m
in
 (I
QR
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.1–
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5.2
)
In
 pa
tie
nt
s w
ith
 A
RC
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% 
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he
ra
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ut
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tio
ns
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% 
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RC
 
gr
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p
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ive
n
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a 
(2
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1]
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nc
om
yc
in
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kn
ow
n
Co
ho
rt
26
5
M
ixe
d
un
kn
ow
n (
0–
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y)
10
–1
2.4
 kg
 
(ra
ng
e n
ot
 
gi
ve
n)
Ye
s
Ag
e, 
AK
I, 
co
-
m
ed
ica
tio
n
Cm
in
: <
 10
 m
g/
l =
 20
%,
 
10
–1
5 m
g/
l =
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.7%
, 1
5–
20
 m
g/
l 
= 
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%,
 >
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 m
g/
l =
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.3%
No
t g
ive
n
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[4
4]
Va
nc
om
yc
in
< 
2 m
o, 
no
n-
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pa
tie
nt
: 4
5 m
g/
kg
/
da
y i
n 3
 do
se
s
< 
2 m
o a
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tie
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: 3
0 m
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kg
/
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s
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kg
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 m
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3
Se
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is,
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eu
-
m
on
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m
en
in
-
gi
tis
2 y
 (1
 m
o–
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 y)
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3.5
 kg
 
(0
.68
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 kg
)
Ye
s
Ag
e, 
Cm
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gt
h o
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th
er
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M
O 
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y, 
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-
m
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tio
n, 
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of
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so
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2 g
ro
up
s [
1 g
ro
up
 in
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hi
ch
 hi
gh
 
Cm
in
 (1
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20
 m
g/
l) 
we
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 de
sir
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vs
. a
 co
nt
ro
l g
ro
up
 in
 w
hi
ch
 
Cm
in
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 15
 m
g/
l w
er
e d
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M
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e s
ep
sis
 in
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 g
ro
up
, m
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e 
pn
eu
m
on
ia 
in
 co
nt
ro
l g
ro
up
M
ea
n v
an
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m
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in
 co
nc
en
tra
tio
n i
n 
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ig
h’
 g
ro
up
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.8 
m
g/
l ±
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s. 
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e c
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l ±
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1
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Cm
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2]
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om
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in
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m
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en
t d
os
in
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/d
ay
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d i
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us
ed
 in
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 m
in
; c
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tin
u-
ou
s d
os
in
g:
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-
in
g d
os
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5 m
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kg
 in
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in
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m
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 do
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40
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kg
 in
 24
 h
Co
ho
rt
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M
ixe
d
4.1
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 y)
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0 k
g 
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 kg
)
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s
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Cm
in
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m
itt
en
t d
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in
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.7)
AU
C 0
–2
4h
/M
IC
 42
5 (
IQ
R 
29
3–
49
7)
, 
fA
UC
 0–2
4h
/M
IC
 29
4 (
IQ
R 
22
2–
35
7)
 fo
r M
IC
 1 
m
g/
l
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r C
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s
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s r
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in
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eig
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t d
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l, 
tar
ge
t A
UC
 0–2
4h
 of
 
40
0
12
/2
8 p
ati
en
ts 
(4
3%
) 
ha
d t
he
ir 
fir
st 
va
nc
o-
m
yc
in
 pl
ate
au
 co
n-
ce
nt
ra
tio
n b
etw
ee
n 
15
 an
d 3
0 m
g/
l o
n 
da
y 1
, 4
5%
 ha
d t
he
ir 
2n
d c
on
ce
nt
ra
tio
n 
be
tw
ee
n 1
5 a
nd
 30
AU
C 0
–2
4h
 >
 40
0 w
as
 
re
ac
he
d i
n 7
/2
8 
pa
tie
nt
s (
25
%)
 on
 
da
y 1
, 4
/2
3 (
17
%)
 
on
 da
y 2
 an
d 6
/1
9 
(3
2%
) o
n d
ay
 3
No
t g
ive
n
Gi
ac
he
tto
 
(2
01
1)
 
[4
6]
Va
nc
om
yc
in
Pr
ot
oc
ol
: 4
0 m
g/
kg
/
da
y f
or
 ex
tra
m
e-
ni
ng
ea
l i
nf
ec
tio
ns
, 
60
 m
g/
kg
/d
ay
 fo
r 
CN
S 
in
fec
tio
ns
Do
se
s u
se
d i
n 
stu
dy
: m
ea
n 
39
.92
 m
g/
kg
/d
ay
 
(ra
ng
e 3
3–
45
) o
n 
da
y 1
 (n
 =
 22
) a
nd
 
m
ea
n 4
4.1
7 m
g/
kg
/d
ay
 (2
4–
60
) 
on
 da
y 3
 (n
 =
 15
)
Co
ho
rt
22
M
ixe
d
3.2
 y 
(1
 m
o–
16
 
y)
W
eig
ht
 no
t 
gi
ve
n
No
Po
sit
ive
 fl
ui
d 
ba
lan
ce
Va
nc
om
yc
in
 C
l o
n d
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n d
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n d
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n d
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/
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/
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n d
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g d
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n m
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 C
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.0–
64
.8)
Cm
in
 12
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(ra
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.5–
53
.3)
Cm
in
 11
.7 
m
g/
l ±
 6.
8 (
ra
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(ra
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IS
M
, P
IM
-2
, 
de
hy
dr
ati
on
, 
EC
M
O,
 pa
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) f
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 m
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eig
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in
 
em
pi
ric
 do
se
 
59
.23
 m
g/
kg
/
da
y ±
 49
.85
 (I
QR
 
39
–7
9)
. T
he
 
in
ter
va
l b
etw
ee
n 
do
se
s v
ar
ied
 fr
om
 
6 t
o 4
8 h
Co
ho
rt
94
Ca
nc
er
7.2
8 y
 (2
 
m
o–
17
.6 
y)
22
.3 
kg
 (I
QR
 
11
.1–
35
.7 
kg
)
Ye
s
Ag
e, 
we
ig
ht
, 
va
nc
om
yc
in
 
co
nc
en
tra
-
tio
n, 
ste
m
 ce
ll 
tra
ns
pl
an
tat
io
n, 
co
-m
ed
ica
tio
n
Cm
in
 15
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Prolonged infusion of 1 h increased PTA to 25–100%. The 
authors propose a daily amoxicillin dose of 150 mg/kg/day 
in six doses. Duration of infusion is dependent on renal func-
tion, with an extended infusion in children with cystatin C 
concentrations < 1 mg/l.
3.1.1.2 Piperacillin and Tazobactam Five studies reported 
PK-parameters of piperacillin with or without the addition 
of the β-lactamase inhibitor tazobactam [3, 23–26]. Median 
doses used ranged from 300 to 400 mg/kg/day in 3–4 doses, 
with 1 study using a prolonged infusion time of 4  h [23] 
and 1 study not reporting exact dosing schedules used in 
the study [3]. In total 153 patients were included in these 
5 different studies, with a median age of 0.8–5 years and 
ages ranging from 0.1 to 18  years. Risk of mortality was 
reported in 1 study [25], with a median PRISM-score of 8 
(range 0–40) and median PELOD scores, reported in 2 stud-
ies [25, 26], ranged from 1 to 10. Patients with renal dys-
function were largely excluded from analyses, with only 1 
study including 1 patient with renal dysfunction within the 
cohort [26].
Reported median piperacillin Vd ranged from 0.240 to 
0.444 l/kg with the study cohort consisting of predominantly 
septic, neutropenic and/or burn patients showing the highest 
Vd [24]. Cl ranged from 0.190 to 0.299 l/kg/h. Patients from 
the cohort with the lowest median piperacillin Cl still had a 
particularly high median eGFR of 142 ml/min/1.73 m2 based 
on serum creatinine[26].
Four of the 5 studies used a PopPK approach and data was 
best described by a 2-compartment model in 2 studies [24, 
25]. In 2 other studies a 1-compartment model best fitted the 
data, probably because of the use of an extended infusion 
time [23] or a lack of samples in the distribution phase [26]. 
All models included weight as a covariate for Vd and/or Cl. 
Additional covariates that were included in the final models 
of these studies were post-menstrual age with a maturation 
coefficient [25] and eGFR [26] as a covariate for piperacil-
lin Cl and PELOD-2 scores for Vd [26]. Nichols et al. [23] 
included gender as a covariate in their final model for tazo-
bactam Cl. Other covariates that were tested for significance 
but were not included in the final models include cystatin 
C based eGFR, PRISM-scores, reason for admission, and 
co-medication [25].
Target attainment of piperacillin was tested for multiple 
targets and dosing schemes using Monte Carlo simulations 
in all four modelling studies. Three of these four used the 
same target of fT > MIC of 50% against an MIC of 16 mg/l, 
reflecting the clinical breakpoint of Pseudomonas aerugi-
nosa [23–25]. Simulations in all studies concluded extended 
infusion over > 1 h is needed to reach a PTA of > 90%, but 
proposed daily piperacillin doses varied, ranging from 
300 mg/kg/day by Nichols et al. up to 600 mg/kg/day by 
Béranger et al.
3.1.2  Cephalosporins
3.1.2.1 Cefotaxime While three studies were found report-
ing cefotaxime PK in critically ill children [27–29], most 
children in the study by Von Hattingberg et  al. were neo-
nates, with only two patients > 1  month of age included 
in the PK analysis [27]. Doses used varied from 100 to 
300  mg/kg/day in 3–4 daily doses, with patients > 50  kg 
receiving adult doses of three daily doses of 1000 mg in the 
study by Béranger et al. [28]. Although the exact reason for 
admission was only clear from the study by Hartman et al. 
[29], organ dysfunction scores and length of PICU stay was 
reported in two studies [28, 29]. Organ dysfunction scores 
and disease severity were highest among the meningococ-
cal septic shock patients studied by Hartman et al. PELOD 
scores were included in both the model building and valida-
tion cohorts by Béranger et al. [28].
Vd and Cl were reported by Von Hattingberg and 
Béranger et  al. For the typical study patient (weighing 
10.9 kg and 23.7 months of age) in the study by Béranger 
the median Vd and Cl were 0.31  l/kg and 0.334  l/kg/h, 
respectively. The authors used allometric scaling based on 
both body weight and postnatal age to predict individual 
cefotaxime Cl. The two patients in the study by Von Hat-
tingberg et al., one with and one without kidney injury, had 
a Vd of 0.16 and 0.31 l/kg and Cl of 0.109 and 0.479 l/kg/h, 
respectively. Elimination t½ of cefotaxime were similar in 
both studies, ranging from 0.34 to 1.15 h in the study by 
Béranger et al. and 0.46–1.02 h for the two patients without 
and with kidney injury by Von Hattingberg et al.
Both studies used a one-compartment model to describe 
PK parameters, possibly due to the limited sampling strategy 
with a median of two samples per patient. The co-variates 
studied by Béranger et al. include weight, age, serum cre-
atinine, and PELOD-scores [28]. Only weight and age were 
included in the final model as significant covariates on Cl 
and/or Vd. Monte-Carlo simulations were performed with 
several dosing regimens to identify the needed dose to reach 
the target of fT > MIC and fT > 4xMIC of 100%, against 
MIC values of 0.5 mg/l. The authors concluded that inter-
mittent dosing without prolonged infusion, for patients over 
1 month of age, would require a daily dose of 4500 mg/kg to 
reach these targets. However, continuous dosing of 100 mg/
kg/day would be sufficient to reach adequate targets in all 
age groups. Therefore, the authors advised to use continu-
ous dosing for optimal cefotaxime dosing in critically ill 
children.
The study by Hartman et  al. found a slightly higher 
percentage of target attainment (71.3%) for the PD-target 
of fT > 4xMIC of 100% against an MIC of 0.5 mg/l using 
standard doses. Higher MIC values of 1 and 4 mg/l, that 
might be more clinically relevant, showed a lower target 
attainment of 55.1% and 14.7%, respectively. The authors 
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state that this is a best-case scenario of target attainment, 
as samples were randomly drawn across the dosing interval 
and no PK model to simulate actual probability of target 
attainment was developed.
3.1.2.2 Cefuroxime We identified only one study on cefuro-
xime PK in PICU patients [30], 15 patients in total, includ-
ing 4 non-critically ill patients with pharyngitis. The 11 
PICU patients were divided in 2 groups: a severely ill group 
of 5 PICU patients not requiring mechanical ventilation, and 
a very severely ill group with 6 patients requiring mechani-
cal ventilation. No severity of illness scores were provided. 
All patients were treated with a cefuroxime dose of 400 mg/
kg/day in four doses as intermittent infusions over 30 min.
Both Vd and Cl were higher in mechanically ventilated 
patients compared to control and PICU patients that did not 
require mechanical ventilation. Even though differences 
between Vd and Cl between control and non-intubated 
PICU patients were minimal, t½ of cefuroxime was longer 
in both critically ill groups compared to the control patients 
(1.0–1.3 h vs. 0.5 h).
The study used both 1- and 2-compartment models to 
describe the obtained PK-data, for each individual patient. In 
the majority of patients (8/11) a 2-compartment model gave 
the best fit of the observed data. No dosing advice was given 
to account for these PK changes in critically ill patients.
3.1.2.3 Cefazolin Three cefazolin studies were included in 
our review, all conducted before, during or after cardiopul-
monary bypass (CPB) [19, 20, 31]. One study included only 
patients under 10 kg bodyweight and up to 2.6 years of age 
[31] while the other 2 studies basically covered the whole 
pediatric age range from birth to 16 years old [19, 20]. Used 
cefazolin doses varied between the 3 studies with de Cock 
et  al. and Cies et  al. both using 25  mg/kg/dose preopera-
tively and during CPB and Haessler et al. using 40 mg/kg 
preoperatively and 105  mg/kg/day in 3 doses in the days 
after surgery. Interestingly, Cies et al. also added a dose of 
25 mg/kg bodyweight cefazolin to the CPB primer solution 
to ensure stable antibiotic levels during CBP.
In the study by Haessler et al. cefazolin concentrations 
during and after surgery showed a mean Cmax of 166 mg/l 
and a steady-state Cmin of 15 mg/l was reached [31]. Elimi-
nation rate constants of cefazolin were significantly lower 
during CBP (0.331/h) and significantly higher after surgery 
(1.429/h) compared to before surgery (0.738/h). In addition, 
the Vd increased during CBP due to increased blood vol-
ume during extracorporeal circulation (0.357 l/kg compared 
to 0.191 l/kg before surgery). After surgery Vd returned 
to baseline values (0.127 l/kg). This increase in Vd dur-
ing CPB was also seen by de Cock et al. who used a CPB-
compartment ranging from 150 to 1000 ml in their model. 
The mean population values for Cl and Vd in their model, 
0.229 l/kg/h and 0.635 l/kg respectively, show a comparable 
elimination rate constant but a higher Vd, possibly due to 
including older patients in their cohort. PK parameters in the 
study by Cies et al. are hard to compare with the other stud-
ies due to their alternative dosing strategy, giving markedly 
lower clearance values of roughly 0.0005 l/kg/h. Volume 
of distribution values found by Cies et al. were comparable 
with those found by de Cock et al., except for the oldest age 
group of 4–16 years old.
Both de Cock et al. [19] and Cies et al. [20] used a PopPK 
approach by using a 2-compartment and 1-compartment 
model, respectively. Both models included bodyweight and 
age in their final models, with de Cock et al. also including 
eGFR as a covariate for Cl and albumin concentrations as a 
covariate for protein binding. Dosing simulations were per-
formed only by de Cock et al., using a PD-target of 50–100% 
fT > MIC against MICs ranging from 0.125 to 16 mg/l. They 
conclude that the standard dosing regimen of 25 mg/kg/dose 
shows a PTA of roughly 50%, while the optimal dosing regi-
men that used doses up to 40 mg/kg/dose showed a PTA of 
88–99%. Cies et al. conclude that adding cefazolin to the 
CPB primer solution ensures stable, adequate concentra-
tions of cefazolin throughout surgery, but more research is 
needed.
3.1.2.4 Ceftaroline Cies et  al. mentioned TDM outcomes 
in 7 patients treated with non-standard (higher) doses of 
60 mg/kg/day in 4 doses in a paper on multiple antibiotics 
[3]. The majority of patients did not require an additional 
dose alteration to achieve target attainment.
Cies and colleagues also published a case series of 7 
patients treated with ceftaroline, presumably the same 
patients as mentioned in the previous publication, which 
is the only PK-data of ceftaroline we identified [32]. All 
patients were treated for a suspected MRSA infection and 
patients with an estimated creatinine clearance below 60 ml/
min/1.73 m2 were excluded. Patients started with a non-
standard dose of 54–60 mg/kg/day, but dosing regimens 
were altered to reach the target of fT > 4–6 × MIC for 40% of 
the dosing interval, with MICs ranging from 0.38 to1 mg/l. 
Individual PK-parameters for several dosing regimens are 
mentioned, but for the starting regimen median Vd, Cl and 
t½ were 0.41 l/kg, 0.218 l/kg/h and 1.3 h. The authors com-
pare their observed PK-parameters to the PK-parameters 
for healthy pediatric patients in the package insert. The 
patients in the study showed a higher median Vd (0.41 l/
kg), higher Cl (0.218 l/kg/h) and shorter t½ (1.3 h) than 
the package insert estimates, which were 0.28 l/kg, 0.138 l/
kg/h and 2.7 h, respectively [33]. All patients required a 
dose alteration or a non-FDA-approved dose to reach tar-
get attainment, and all patients eventually were cured from 
their MRSA infections. The authors advise a 6-h dosing 
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interval in bloodstream infections, pneumonia or meningitis 
with MRSA and a dose of 15 mg/kg/dose in patients with 
increased Vd.
3.1.3  Carbapenems
3.1.3.1 Meropenem For meropenem 1 case report and 1 
PopPK model, both by Cies et al., were identified [34, 35]. 
The case report describes a 2-year-old girl with a Serratia 
marcescens ventriculitis [34]. She was treated with 150 mg/
kg/day intermittent infusions for 30 min, but this resulted 
in undetectable meropenem plasma concentration 4 h after 
dosing. Eventually she was successfully treated with an 
increased dose of meropenem of 200 mg/kg/day as a con-
tinuous infusion, reaching plasma concentrations of 13 mg/l 
and CSF concentrations of 0.5 mg/l. The calculated Cl of 
this patient was 0.612 l/kg/h. The authors claim this clear-
ance is higher than reported values in healthy adults and 
critically ill children on extracorporeal membrane oxygena-
tion, but exact numbers are not reported.
The 2017 PopPK model by Cies et al. included data from 
9 patients treated with doses ranging from 40 to 200 mg/kg/
day [35]. Most patients received intermittent infusions in 
30 min, 2–4 times per day. One patient was treated with con-
tinuous infusion of 200 mg/kg/day and one patient received 
100 mg/kg/day in 2 daily doses as prolonged infusions 
for 2 h. Median (range) age of patients was 2 (1–9) years. 
No patients with renal dysfunction were included, and the 
median eGFR was 168 ml/min/1.73 m2, indicating possible 
ARC within the study population.
A roughly 2 times larger Vd (0.78  l/kg) and slightly 
higher Cl (0.419 l/kg/h) were described in this cohort by 
Cies et al. [35]. compared to other studies in clinically stable 
pediatric patients by Du et al. [36] and Blumer et al. [37] 
(Vd 0.2–0.43 l/kg and Cl 0.18–0.34 l/kg/h, respectively).
After a sparse sampling scheme with a total of 16 mero-
penem concentrations a Pmetrics 2-compartment PopPK 
model was used to estimate PK. Weight, age and creatinine 
clearance were considered to be significant covariates for 
Vd and/or Cl.
Target attainment of 40% fT > MIC was only reached in 
simulations of dosing regimens with prolonged or continu-
ous infusion of 120–160 mg/kg/day, with MICs ranging 
from 0.25 up to 2 mg/l. Target attainment of 80% fT > MIC 
was only reached with continuous infusion for MICs up to 
2 mg/l. For higher MICs, the PTA was below 90% in all 
simulations.
3.1.3.2 Imipenem Gianonni et  al. studied imipenem PK 
in 19 critically ill children ranging from 9 days to 12 years 
of age [38]. Patients were treated with 100 mg/kg/day in 
3–4 daily 30-min infusions. The median (range) PRISM 
score was 9 (0–23) and although patients with renal dys-
function were included, the exact number of patients with 
impaired renal function is unclear.
A non-compartmental analysis was performed to esti-
mate Cl, t½ and Vd of imipenem in critically ill children 
after the first dose and at steady state. All PK-parameters 
slightly increased from first dose to steady state. The 
authors compared their findings to other studies in (non-
critically ill) children with imipenem. PK-parameters were 
within the reported values for pediatric patients, with a 
slightly lower Cl, higher Vd and a longer t½ in critically 
ill patients. Moreover, the correlation between several 
covariates and the PK-parameters was tested, including 
age, weight, creatinine clearance, albumin, lactate, dis-
ease severity, blood pressure and heart rate. Eventually, Cl 
parameters correlated best with creatinine clearance, mean 
arterial pressure and lactate acidosis, although it is unclear 
how creatinine clearance was measured or estimated.
3.1.4  Other Penicillins
3.1.4.1 Aztreonam The only PK-data on aztreonam, a 
broad-spectrum monobactam antibiotic agent, is found 
within a case-report by Cies et al. [39]. In this case-report 
the authors describe a case of a 16-year-old tetraplegic 
patient with a pneumonia caused by a multi-resistant Pseu-
domonas aeruginosa [39]. This pathogen was susceptible 
to aztreonam against an MIC of 6 mg/l and the patient was 
treated with aztreonam 8 g/day in 4 prolonged infusions of 
4 h. Cl was 0.138 l/kg/h, almost double of the adult Cl val-
ues reported in the package insert (0.078 l/kg/h) [40]. The 
used dose resulted in plasma concentrations above 6 mg/l 
for at least 40% of the time with a Cmax of 71 mg/l.
3.2  Glycopeptide Antibiotics
3.2.1  Vancomycin
A total of 17 studies reporting PK-parameters of vancomy-
cin in critically ill children were identified by the search, 
with more than 1000 PICU patients included in total 
over the whole pediatric age range [41–57]. Most studies 
included a mixed population, but also specific populations 
(such as patients with hematologic/oncologic [43, 45], car-
diac [51, 53, 56, 57], traumatic [50] and infectious dis-
eases [44, 48]) being studied separately. Four studies [42, 
43, 46, 48] were prospective PK studies and the remaining 
13 studies were based on TDM data.
Most studies used intermittent dosing with daily doses 
of vancomycin ranging from 30 to 60 mg/kg/day, with only 
1 study reporting higher mean doses (81 mg/kg/day) [45] 
and 1 study not mentioning the dose at all [41]. Two studies 
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reported data on continuous dosing schedules, using a load-
ing dose of 15 mg/kg and a maintenance dose of 40–45 mg/
kg over 24 h [42, 55].
Vancomycin is predominantly cleared by glomerular fil-
tration and is also associated with nephrotoxicity, therefore 7 
studies mainly reported findings on the effect or occurrence 
of acute kidney injury (AKI) and/or ARC in patients treated 
with vancomycin [41, 44, 49, 50, 52, 54, 56]. Several studies, 
including 2 studies with over 250 patients, reported conflict-
ing results regarding vancomycin Cmin in patients with and 
without AKI. Bonazza et al. [41] showed increased Cmin in 
patients with AKI whereas Totapally et al. [49] and Holsen 
et al. [54] both found no significant differences in Cmin and/
or Cmax between patients with and without AKI. To identify 
whether higher vancomycin Cmin lead to kidney injury Cies 
et al. performed a retrospective study comparing 2 groups, 
with either a high (15–20 mg/l) or low (10–15 mg/l) target 
Cmin of vancomycin [44]. The incidence of AKI was not 
significantly different between these 2 groups.
ARC is the main focus of 2 studies, 1 case report [50] 
and 1 cohort study with 250 patients aged 0–21 years old 
[52]. ARC was defined by an estimated creatinine clearance 
of > 150 and > 160 ml/min/1.73 m2 by Goboova et al. [50] 
and Avedissian et al. [52], respectively. The patient in the 
case report required a doubling and tripling of the initial 
dose (from 2 g/day in 2 doses to 4–6 g/day in 2 doses) to 
reach therapeutic Cmin of 10–15 mg/l. Avedissian et al. 
found 29 patients with ARC, 12% of their total cohort [52]. 
PK data were analyzed using pop-PK with NONMEM. 
Patients with ARC were significantly older and had lower 
baseline serum creatinine levels. PK-parameters for vanco-
mycin were significantly different in patients with ARC: they 
had lower median Cmin, higher median Cl, larger median 
Vd and a shorter median t½. Subtherapeutic drug concentra-
tions were more common in patients with ARC compared to 
patients without ARC (79% and 58%, respectively), but this 
difference was not statistically tested. Both age and serum 
creatinine were independent covariates for Cl. Weight was 
the only independent covariate for Vd.
Of the 17 vancomycin articles, 8 reported Cmin and/or 
Cmax as the only PK-parameters. Six of these have already 
been discussed in the previous paragraphs regarding AKI 
or ARC [41, 44, 49, 50, 54, 56]. The 2 remaining articles, 
by Glover et al. [47] and Thomas et al. [53], both included 
patients with a normal renal function at the start of treat-
ment. Both studies analyzed PK-parameters in steady state 
after the initial dose, while Glover et al. also looked at the 
final doses used after TDM. After the initial therapy with a 
mean dose of 47.3 mg/kg/day mean Cmin were 6.2 mg/l on 
average [47]. Mean doses after TDM were roughly 60 mg/
kg/day, resulting in higher mean Cmax and Cmin of 26.0 and 
7.8 mg/l, respectively. The authors advised to use 60 mg/
kg/day in critically ill patients with normal renal function 
to ensure optimal target attainment, but do not specify the 
desired target concentrations. Thomas et al. included both 
neonates, infants and children in their study [53]. They found 
that roughly 50% (39 of 77) of patients reach adequate Cmin 
(using a dose of 30–40 mg/kg/day and a target Cmin between 
8 and 15 mg/l) and sub- and supratherapeutic concentrations 
in 31.2% and 18.2% of patients, respectively. Multivariable 
regression analysis identified age, weight and creatinine 
clearance at the start of treatment as significant co-variates 
for vancomycin Cmin.
Cmin measurements are mainly used for TDM as a sur-
rogate parameter of the true PD target of vancomycin used 
in adults (AUC/MIC > 400) and is commonly extrapolated 
to pediatric patients. Several studies determined, simulated 
or estimated AUC/MIC in their analysis [42, 43, 45, 46, 
54, 55, 57]. Giachetto et al. reported vancomycin AUC 0–24h/
MIC on both day 1, using an initial dose of 33–45 mg/kg/
day, and after TDM on day 3 for MICs of 1 and 2 mg/l [46]. 
Mean AUCs for day 1 and day 3 were 364 mg/l/h for both 
days, with roughly 50% of patients reaching the target of 
AUC/MIC > 400 for the MIC of 1 mg/l and 5–7% for the 
MIC of 2 mg/l. Simulations with several dosing regimens 
in the study by Moffett et al. [57] showed a target attain-
ment of > 90% for regimens using 60 mg/kg/day in 3–4 doses 
and a target attainment ranging from 33.2 to 60% for dosing 
regimens with a lower daily dose of 40–45 mg/kg/day in 2–4 
doses. Other studies reporting AUC/MIC data all reported 
similar percentages of target-attainment of approximately 
50%, with only Genuini et  al. [55] (using a continuous 
dose of 45 mg/kg/day) reporting lower target attainment of 
17–32%. De Cock et al. also included 3 patients with con-
tinuous dosing, but no separate PK-parameters for these 3 
patients were presented [42]. The study by de Cock et al. was 
the only study including free AUC/MIC values, with a target 
of fAUC 0–24h/MIC > 200 assuming an unbound fraction of 
50% [42]. The measured unbound fraction of vancomycin 
in their study was higher than this assumption (71.1%). The 
majority of patients (83%) reached this unbound vancomy-
cin target using a dose of 60 mg/kg/day. When using Cmin 
between 5 and 10 mg/l as a surrogate target, only 8% of 
patients reach this target, questioning the validity of this 
surrogate target in critically ill pediatric patients.
Other PK-parameters presented in several studies include 
Cl and Vd in 7 studies [43, 45, 46, 48, 51, 52, 57], with 2 
studies reporting data on vancomycin t½ [48, 52]. Mean 
Vd within each study ranged from 0.44 to 1.04 l/kg, with 
a median Vd among studies of 0.77 l/kg. Mean Cl in each 
study ranged from 0.072 to 0.19 l/kg/h, with a median of 
0.154 l/kg/h found among studies. Avedissian et al. and Gous 
et al. both reported a similar t½ (3.4 and 3.62 h, respectively) 
[48, 52].
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3.2.2  Teicoplanin
Three prospective studies describe teicoplanin PK in criti-
cally ill children with ages ranging from 7 days to a maxi-
mum of 12 years old [18, 58, 59]. Doses used in studies var-
ied, with 2 studies [58, 59] using 3 loading doses of 10 mg/
kg teicoplanin every 12 h and afterwards a maintenance 
dose of 10 mg/kg every 24 h. The study by Lukas et al. was 
designed as a randomized controlled trial where patients in 
the other study arm received a higher maintenance dose of 
15 mg/kg every 24 h [58]. One study, by Reed et al., used 
lower daily doses of 6 mg/kg in patients undergoing cardiac 
or head surgery, without information on whether a loading 
dose was given [18].
Sanchez et al. described 21 patients, mainly post cardiac 
surgery, including 1 patient with renal dysfunction with an 
eGFR of 55 ml/min/1.73 m2 [59]. A total of 127 samples 
were drawn, with a full PK-curve after the first dose of 
teicoplanin and Cmin 1, 2, 3 and 7 days after the first dose. 
PK-parameters were determined by a non-compartmental 
analysis using an open 2-compartment model. Mean Cmax 
values at 0.5 h were 26.2 mg/l, Cmin at steady state were 
5.8 mg/l and mean AUC was 224.5 mg/l/h. Vd at steady state 
was 1.02 l/kg and total Cl was 0.045 l/kg/h and a terminal t½ 
of 17.41 h. PK-parameters are presented without an indica-
tion of variance, which makes extrapolation to other cohorts 
difficult. The authors used a target of > 10 mg/l, which was 
reached in only 11% of Cmin samples. Teicoplanin concen-
trations and PK-parameters did not differ between patients 
under 3 months, 3–12 months and over 12 months of age 
although it is unclear how many patients were represented 
in each age group and the overall group size was relatively 
small.
As mentioned before, Lukas et al. performed a rand-
omized controlled trial with half of the patients receiving a 
larger maintenance dose [58]. However, no significant differ-
ences in teicoplanin concentrations were observed between 
these 2 dosing strategies. The authors did find a significant 
difference between young infants (aged < 12 months) and 
older children (> 12 months), with a lower target attainment 
in older children (65%) compared to young infants (92%). 
Further analyses in this study focused on the differences in 
PK-parameters between these 2 age groups, regardless of the 
randomized maintenance dose. Children > 12 months had a 
higher Cl, larger Vd and longer t½ (3.9 l/kg/h, 0.29 l/kg and 
9.32 h, respectively) compared to younger infants (1.05 l/
kg/h, 0.09 l/kg, 8.1 h, respectively). The authors concluded 
that for younger infants 3 loading doses of 5 mg/kg every 
12 h followed by 4 mg/kg once daily would be sufficient 
to reach adequate target attainment. For older children, 
the authors advise 3 loading doses of 10 mg/kg every 12 h 
and subsequently 8 mg/kg once daily as maintenance dose. 
Interestingly, this is a lower maintenance dose than used in 
the study population that showed limited target attainment.
Reed et al. [18] included 12 patients with a median age 
of 6 years; 11 after cardiac surgery and 1 with head surgery. 
Teicoplanin PK-parameters were determined after the 1st 
and 5th dose in a 3-compartment model using PCNONLIN. 
Cmax and Cmin were 39.3 mg/l and 1.8 mg/l, respectively, 
after the first dose and 40.8 mg/l and 3.1 mg/l, after the fifth 
dose. After the first dose, Vd was 0.46 l/kg and total Vd in 
steady state, after the 5th dose, was 0.56 l/kg. Total body Cl 
after the first dose was 2.38 l/kg/h, with renal Cl contribut-
ing for 1.09 l/kg/h of total Cl. After the 5th dose only total 
body Cl was determined at 2.19 l/kg/h. Terminal t½ was 
11.3 and 16.3 h after the first and fifth dose, respectively. 
No additional covariates were identified for their influence 
on teicoplanin PK. The authors recommended using higher 
doses (than the 6 mg/kg once daily used in this study) of 
teicoplanin in critically ill children, 8 mg/kg every 12 h 
to reach Cmin of > 10 mg/l and 15 mg/kg every 12 h for 
Cmin > 20 mg/l (e.g. in case of endocarditis).
3.3  Aminoglycoside Antibiotics
3.3.1  Gentamicin
Haessler et al., also determined gentamicin concentrations 
before, during and after cardiac surgery in children < 10 kg 
[31]. During surgery, gentamicin Cmax reached 20.8 mg/l 
and mean Cmin on day 2 and 3 were 1.1 (SD 0.5) mg/l and 
0.8 (SD 0.4) mg/l, respectively. Like the results for cefazo-
lin, as discussed above, k for gentamicin declined during 
surgery (0.336/h) compared to baseline (0.962/h). However, 
contrary to cefazolin data, the k remained significantly lower 
after surgery (0.188/h). Vd also showed a different pattern 
for gentamicin than cefazolin. Vd increased during surgery 
(0.237 l/kg before surgery to 0.400 l/kg during surgery), 
in concordance with cefazolin data. However, Vd remained 
increased after surgery (0.624 l/kg) compared to baseline, 
and was even larger than the Vd during surgery.
Three other studies report PK-parameters of gentamicin 
in critically ill children [60–62]. The study by Kraus et al. 
[62] used a dosing scheme of multiple daily doses, whereas 
the other 2 studies used a single daily dose [60, 61]. Kraus 
et al. used doses ranging from 1.8 to 3.1 mg/kg/dose with 
2–3 daily doses, with the majority of patients (39/44) receiv-
ing 3 daily doses [62]. The group of 44 patients was divided 
in 2 groups based on the number of gentamicin Cmax and 
Cmin concentrations that were available. The group with 
only 1 set of Cmax and Cmin concentrations (n = unknown) 
was used to determine population-based PK-parameters, 
which were validated in the other group of patients with 
multiple sets of Cmax and Cmin concentrations. The 
population-based values for Vd, Cl and t½ were 0.416 l/
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kg, 0.114 l/kg/h and 2.8 h, respectively. PK-parameters for 
the validation group with multiple sets of Cmax and Cmin 
concentrations were not significantly different from these 
population-based values. There was no correlation between 
age or post-operative status and PK-parameters. Dosing sim-
ulations were performed using the population-based values, 
with Cmax = 7 mg/l and Cmin = 1 mg/l as predefined target. 
A mean daily dose of 9.1 mg/kg/day (range 5.2–14.8 mg/kg/
day) divided in 2–6 daily doses was predicted to reach these 
target concentrations.
Lopez et al. used a dosing scheme of 8 mg/kg every 
24–36 h [61]. The actual dose used in the study by Zakova 
et al. is unknown, but Monte-Carlo simulations for target 
attainment were performed with a simulated dose of 6 mg/
kg every 24 h [60]. Both studies used a mixed patient popu-
lation; with Zakova mainly using younger children, aged up 
to 21 months and Lopez et al. including older patients up 
to 14 years old (and including 14 neonatal patients as well 
that are not included in this review). Both studies included 
patients with renal dysfunction, 10% of patients in the study 
by Lopez et al. required renal replacement therapy, but for 
both studies it is unclear how many patients actually suffered 
from any form of renal dysfunction.
Several co-variates were tested for their influence on 
PK-parameters; both studies identified age and weight as 
significant co-variates for Vd and/or Cl. Serum creatinine 
was correlated with the k in the study by Zakova [60], but 
was not found to improve the model of Lopez et al. [61]. 
Other tested co-variates by Zakova et al. were gender, co-
medication, admission unit, PRISM-scores and serum albu-
min, with only the admission unit (PICU or Cardiac Critical 
Care Unit) being significantly correlated with Vd and k in 
multiple regression analysis [60].
The 2 measured PK-parameters by Zakova et al. are Vd 
and the k [60]. Values for Cmax, AUC and the drug-free 
interval were simulated using Monte-Carlo simulations. 
Median Vd was 0.39 l/kg and k 0.18/h. Using a simulated 
dose of 6 mg/kg every 24 h, median Cmax, AUC and drug-
free interval values were 17.6 mg/l, 78.6 mg/l/h and 15.2 h. 
The simulated dosing scheme of 6 mg/kg resulted in 28.4% 
of patients within the Cmax target of 16–20 mg/l (38.8% 
below, 32.8% above), 22.4% of patients within AUC target 
of 70–100 mg/h/l (37.3% below, 40.3% above) and 53.7% of 
patients within the drug-free interval target of 4–16 h (6% 
below, 40.3% above).
Lopez et al. used non-linear mixed effect modelling to 
determine population-based PK-parameters in a 2-compart-
ment model [61]. Mean population value for Cl was nor-
malized for a 70 kg patient at 2.09 l/h/70 kg, with age and 
weight being significant co-variates for individual Cl val-
ues. Vd of the peripheral compartment was fixed at 3.78 l 
and the volume of the central compartment was 0.35 l/kg. 
Target attainment was defined as Cmax > 16 mg/l and was 
determined for different daily doses up to 8 mg/kg of gen-
tamicin. This target was reached in all non-neonates using a 
dose of 7–8 mg/kg, but the authors stated that dosing inter-
vals should be extended in younger infants due to age-related 
changes in renal Cl and the risk of toxicity in the case of 
gentamicin accumulation.
3.3.2  Amikacin
One randomized controlled trial (RCT) and 2 cohort 
studies on the PK of amikacin were found [63–65]. The 
RCT, performed by Marik et  al. included 60 pediatric 
patients < 1 year of age that were treated with amikacin 
20 mg/kg/day [63]. Patients were randomized to either 
a once daily dosing scheme, including a loading dose of 
20–25 mg/kg, or a twice daily dosing scheme without a 
loading dose. Data was analyzed using a 2-compartment PK 
model using NONLIN. The pediatric patients under 1 year 
were split into 2 groups of 30 patients based on age, a group 
of patients aged < 6 months (median age 8 weeks) and a 
group of children 6–12 months (median age 28 weeks). Chil-
dren older than 1 year were included in a group also includ-
ing adults (median age 34 years). Vd in patients < 1 year 
was larger (0.58 and 0.50 l/kg for patients < 6 months and 
6–12 months, respectively) than older patients (0.33 l/kg). 
In addition, Cl was higher in younger patients 0.063 and 
0.068 l/kg/h vs. 0.051 l/kg/h in older patients. Elimination 
t½ was longest in children < 6 months (5.02 h) and short-
est in children 6–12 months (2.86 h). Target-attainment, 
defined as Cmax > 20 mg/l and Cmin < 5 mg/l, was 100% in 
the group with once daily dosing and 79% (Cmax target) and 
44% (Cmin target) for twice daily dosing. Children required 
higher daily doses in mg/kg to reach these targets: 21 mg/kg/
day for 6–12 months, 18.6–20.5 mg/kg/day for < 6 months 
and 13.8–15.5 mg/kg/day for older patients.
The 2 other studies used a cohort of patients treated with 
amikacin, with Bressolle et al. including both children and 
adults in their 2-compartment model [64]. Patients received 
doses ranging from 70 to 1500 mg, however the dose in mg/
kg/day the pediatric patients received is not reported. The 
only PK-data that was separately presented for the pediatric 
population were Cmax and Cmin values. Mean Cmax and 
Cmin values in the pediatric study population were 40.7 and 
0.97 mg/l, respectively. These values were validated in a 
test-population of 8 additional children, which showed lower 
Cmax of 16.0 mg/l and higher Cmin, 1.40 mg/l. After Bayes-
ian estimation for children, predicted concentrations for 
Cmax and Cmin were 16.2 mg/l and 1.45 mg/l, respectively.
Sherwin et al. only included patients with burns in their 
study, with a median burned surface area of 43% [65]. Both 
studies by Bressolle and Sherwin used a wide pediatric 
age range from 6 months to 15 and 17 years, respectively, 
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and both studies included patients with renal dysfunction 
[64, 65]. Studied covariates included weight and height, 
and Sherwin et al. also tested age, gender, percentage of 
burned surface area and serum creatinine as covariates, 
but none improved the model significantly [65]. Popula-
tion parameters for Cl and Vd were normalized for a typical 
70 kg patient. Amikacin Cl was 5.98 l/h/70 kg and Vd was 
16.7 l/70 kg for the central compartment and 40.1 l/70 kg for 
the peripheral compartment. These values are higher than 
the Cl and Vd of the previously discussed study by Marik 
et al. [63], indicating altered PK in burn patients.
3.3.3  Netilmicin
Only 1 study on netilmicin PK in pediatric patients was 
available [66]. This study by Wagner et al. mainly included 
neonatal patients; only 9 of the total of 66 patients, with a 
mean age of 4.6 years were admitted to the pediatric ICU. 
Patients were treated with a once daily dose of 6 mg/kg. 
The authors mentioned a reduced dose and prolonged dosing 
interval for patients with renal insufficiency, but no patients 
with renal dysfunction were included in the pediatric cohort. 
The only PK-data that are presented are Cmax and Cmin val-
ues for pediatric patients. Mean Cmax values were 33 mg/l 
(range 23–41 mg/l) and Cmin values were 1.3 mg/l (range 
0.2–3.2 mg/l). The authors concluded that once daily dosing 
of netilmicin is sufficient to reach adequate targets.
3.4  Other Antibiotics Agents with Eligible Studies 
in Our Search
3.4.1  Daptomycin
2 case-reports and 1 pharmacometric model were available 
for daptomycin that included PK parameters [67–69]. Both 
patients in the case reports suffered from cardiac problems, 
a 13 year old boy with endocarditis [67] and a 8 year old 
girl with multi-organ failure (including renal insufficiency) 
awaiting heart transplantation [68]. Similar doses were used 
in both studies (6–8 mg/kg every 24 h). The dose interval 
was prolonged to 48 h for the patient with renal insufficiency 
[68].
Morris et al. only presented steady state Cmax and Cmin 
values, which were 68 mg/l and 14.6 mg/l, respectively [68]. 
These values were within the desired target of Cmin below 
20 mg/l. Akins et al. provided Cmax and Cmin concentra-
tions after a single dose and in steady state [67]. In addition, 
Vd, Cl, t½, k and AUC values were presented for both the 
first dose and in steady state. Cmax were higher and Cmin 
concentrations were lower than the values reported by Mor-
ris et al., both after the first dose as in steady state. Values 
in steady state for Vd and Cl were 0.089 l/kg and 0.0137 l/
kg/h, respectively. t½ in steady state was 4.58 h, with an 
AUC of 594 mg/l/h.
The pharmacometric model by Antachopoulos included 
data of 4 patients aged from 8 to 14 years old with mixed 
disease conditions in their one compartment model [69]. 
On the first day of treatment, 3 of the 4 patients met pedi-
atric criteria for sepsis. The patients with sepsis had a sig-
nificantly higher Cl (median Cl 0.0423 l/kg/h) compared 
to the patient without sepsis (0.0151 l/kg/h). Vd was also 
higher in patients that met sepsis criteria (0.26 l/kg, com-
pared to 0.16 l/kg for the non-sepsis patient). This resulted 
in a lower AUC 0–∞ and lower Cmax values of daptomycin 
in sepsis patients compared to non-sepsis patients (AUC 
0–∞ 236.5 mg/h/l vs. 663.9 mg/h/l and Cmax 35.4 mg/l vs. 
59.8 mg/l, respectively). PK parameters on the 5th day were 
comparable with the first day, with a higher Cl, larger Vd, 
lower AUC 0–24h and Cmax in the 2 patients meeting sepsis 
criteria.
3.4.2  Ciprofloxacin
Lipman et al. published the only study on ciprofloxacin in 
20 patients between 3 months and 5 years with severe sep-
sis [70]. Patients received a daily dose of 20 mg/kg/day in 
2 doses during 1–2 weeks of treatment. The authors used 
non-compartmental analysis to determine PK-parameters 
in 2 age groups, 3 months–1 year and 1–5 years of age. No 
significant differences in PK-parameters between these 2 age 
groups were seen. When using a target of Cmax/MIC = 8, the 
authors concluded that a dose of 20 mg/kg/day is sufficient 
to cover pathogens with an MIC up to 0.8 mg/l. To reach 
the target of AUC/MIC of 100–150 in PICU patients with 
a normal renal function infected by more resistant micro-
organisms the authors advise a daily dose of 30 mg/kg/day 
in 3 doses.
4  Discussion
Although antibiotic use in critically ill children is one of 
the pillars of intensive care treatment, from our review we 
can conclude that current knowledge on the PK and target 
attainment of these drugs in critically ill children is rela-
tively scarce. Nevertheless, an important finding is that tar-
get attainment is often suboptimal in this patient population 
using standard doses of different classes of antibiotics [19, 
21, 24–26, 28, 29, 41, 43, 45, 46, 50, 55, 56, 59, 62, 63, 69].
Not unexpectedly, a large number of manuscripts focus 
on agents where TDM is generally applied during routine 
care, such as vancomycin and gentamicin, as data are rela-
tively readily available from medical records. In contrast, 
to the best of our knowledge, other frequently used agents 
(like ceftriaxone, ceftazidime, penicillin, flucloxacillin, 
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metronidazole) completely lack PK data in the pediatric 
ICU population [71, 72]. In addition, only the minority of 
included articles (22/50) provide dosing guidance for clini-
cians, even though in most publications (38/50) the neces-
sary data on Vd and Cl was available to simulate optimal 
dosing regimens.
When comparing the findings on these different antibiot-
ics in critically ill children to data in critically ill adults and/
or healthy children, it is apparent that PK alterations occur in 
this patient population. For example, Cl values of amoxicil-
lin are almost double in critically ill children (0.24 l/kg/h) 
compared to critically ill adults (0.13 l/kg/h) but with a simi-
lar Vd (0.37–0.47 l/kg in children vs. 0.37 l/kg in adults) 
[73]. For piperacillin, two studies in critically ill children 
show slightly higher Cl values [24, 25] than in critically ill 
adults with hyperfiltration [74], but this is not supported by 
two other publications [23, 26]. Cefotaxime Cl was almost 
50% higher in critically ill children [28] while mean Vd was 
markedly smaller than values reported in non-critically ill 
children [75], resulting in a shorter t½ and higher recom-
mended doses to reach common PD targets. Median values 
of vancomycin Cl and Vd in the studies in this review exceed 
values of non-critically ill children, pediatric cancer patients 
[76, 77] and critically ill adults [78, 79].
These altered PK parameters are most likely the result of 
a combination of disease-related alterations and age-related 
changes in PK [5]. Disease-related changes may impact PK 
by a multitude of pathophysiological mechanisms. Firstly, 
fluid resuscitation is a common therapy for hemodynami-
cally unstable critically ill patients, that may result in an 
increase in total body water, larger Vd and therefore dilution 
of hydrophilic compounds. Systemic inflammatory response 
syndrome (SIRS), caused by inflammatory cytokines, 
induces capillary leak and the shift of intravascular fluid to 
the extravascular space [80]. This ‘third-spacing’ of fluid 
may reduce drug concentrations, not only in plasma but also 
at the site of infection. Furthermore, hypoalbuminaemia is 
common among critically ill children, causing a relatively 
large fraction of unbound drug that is available to distribute 
to peripheral tissues, which mostly influences highly protein 
bound drugs (> 80% protein binding) [42, 81, 82]. These 
alterations in Vd mainly affect concentration-dependent anti-
biotics, such as aminoglycosides which require a high Cmax 
value for optimized bacterial killing [83, 84]. Also, inflam-
mation and critical illness appear to downregulate drug 
metabolism, such as seen with CYP3A-mediated midazolam 
metabolism in critically ill children [85] and CYP2C9-medi-
ated warfarin metabolism in critically ill adults [86].
In addition to changes in Vd, protein binding and drug 
metabolism, renal Cl of drugs can be altered during critical 
illness. AKI in critically ill children is primarily caused by 
reduced renal blood flow (e.g. due to volume depletion or 
decreased arterial blood pressure) and glomerular or tubular 
damage due to cytokine release, disseminated intravascular 
coagulation or nephrotoxic agents [87, 88]. AKI is common 
with a prevalence of around 35% in critically ill children, 
causing a reduced renal Cl and potential supratherapeutic or 
toxic concentrations of renally excreted drugs [89]. While a 
general picture of reduced target-attainment in critically ill 
children may arise from our review, several studies do report 
supratherapeutic plasma concentrations for some of the toxic 
antibiotics like aminoglycosides or glycopeptides in a small 
proportion of patients [41, 43, 53, 63].
This counter-intuitive finding of reduced exposure in 
critically ill children, may be explained by a high incidence 
of ARC. Contrary to AKI, ARC has been identified in up 
to 67% of both critically ill adults [8] and children [10]. 
This is in line with several studies in this review showing 
extremely high drug Cl and/or eGFR in this patient popu-
lation [21, 26, 50, 52]. A recent review by Dhont et al. on 
ARC in children shows that time-dependent antibiotics, like 
β-lactam antibiotics, which require drug concentrations 
above an MIC-threshold for a prolonged period of time, 
could be at the highest risk for non-target attainment due to 
this phenomenon [9]. However, a correlation between ARC 
and subtherapeutic drug concentrations or clinical outcome 
could not be made due to multiple confounding factors that 
also contribute to subtherapeutic drug concentrations and 
adverse outcome of critically ill children.
Furthermore, age-related changes in the processes 
involved in disposition, metabolism and excretion of drugs 
may impact both Vd and Cl. Changes in Vd in neonates and 
young infants may results from a different body composi-
tion, with a higher proportion of body water compared to 
adults [11], mainly influencing hydrophilic compounds like 
the majority of antibiotic agents. Developmental changes 
affecting drug Cl include a lower (absolute) GFR and tubular 
excretion in neonates and children younger than 2 years of 
age [11]. Interestingly, when Cl values are weight-corrected 
the renal clearance reaches adult levels relatively quickly, 
within the first month of life [90]. In addition, weight-cor-
rected GFR is almost 70% higher in 2–5 year old children 
than in adults while renal blood flow and tubular secretion 
stay relatively stable [91]. This relation between age and 
GFR might be contributed to the relatively larger kidney size 
in children compared to adults [90]. Since the majority of 
studies in this review had a median age of included patients 
between 1 and 5 years of age, this could be a possible expla-
nation of the higher weight-corrected Cl compared to adult 
populations.
Lastly, although PD targets for antibiotic agents are 
partially drug-specific, determined by a drugs’ kill-charac-
teristic, and partially defined by pathogenic susceptibility, 
defined as the MIC value, only the former is accounted for 
in dosing recommendations. While MIC-based dosing would 
seem to provide an improvement in the attainment of PD 
Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: Systematic Review
targets, there are numerous drawbacks to using MIC values 
in dosing guidelines as outlined by Mouton et al. [92]. In 
summary, the in vitro MIC assay is insufficiently accurate 
and reproducible to adequately represent conditions in vivo 
and therefore cannot be used as an exact concentration to 
strife for during treatment. Doing so possibly leads to an 
underestimation of the antibiotic effect in vivo [93, 94] or 
missed treatment options [95]. Secondly, the MIC that is 
used in the desired PD targets is regarded as static value 
but should be seen more as a distribution of MICs within a 
bacterial strain [92]. In addition, PD might also be affected 
by alterations in PK [96]. In their semi-mechanistic PK/PD 
model Nielsen et al. have simulated the effects of a wide 
range of dosing regimens of six antibiotics from in vitro 
time-kill curve experiments. The authors state that when 
the PK-profile of benzylpenicillin, a hydrophilic β-lactam 
antibiotic with a short t½, was used for other antibiotics, 
fT > MIC was still the best predictor of effect, even for 
antibiotics that are normally regarded as concentration-
dependent or exposure-dependent. Lastly, the susceptibility 
of pathogens is heavily region-bound, making it difficult to 
extrapolate dosing advices between regions with different 
resistance patterns.
A logic next step seems to incorporate both age- and dis-
ease related co-variates in dosing guidelines using modelling 
and simulation. Most of the PopPK modelling studies in this 
review have incorporated (allometrically scaled) age and/or 
weight covariates in their final models [21, 25, 26, 28, 51, 
52, 55, 57, 61, 65]. However, models incorporating (bio)
markers of organ failure (e.g. eGFR, serum creatinin, albu-
min, C-reactive protein, transaminases) as covariate were 
limited [21, 25, 26, 28, 51, 52, 55, 57]. Of the 48 studies, 
only 5 PK models have incorporated eGFR in their estima-
tions for drug Cl [21, 26, 51, 55, 57] and only 3 additional 
studies found a significant relation between serum creati-
nine and drug concentration [29, 45, 60]. Other studies have 
either not investigated this relationship or found the addi-
tion of creatinine clearance to be non-significant. This might 
reflect that serum creatinine is a suboptimal marker for GFR 
in this population and/or the impact of other factors than 
GFR on the variability in drug clearance. The inability to 
accurately estimate drug clearance using biomarkers is one 
of the fundamental challenges regarding optimizing target 
attainment in this patient population.
In order to overcome suboptimal target attainment of 
antibiotics in critically ill children clinicians have several 
options. Firstly, increasing the dose or dose frequency of an 
antibiotic could provide an easy solution to increase expo-
sure and therefore increase target attainment. However, a 
linear dose increase might introduce increased toxicity and 
will not account for the extremely large within and between 
subject variability in PK seen in critically ill patients caused 
by pathophysiological changes, heterogeneity of underlying 
diseases and extracorporeal circuits seen in PICU patients. 
Secondly, continuous or extended infusion could be used 
for time-dependent antibiotics, like β-lactam antibiotics, in 
order to optimize dosing regimens to the established PK-PD 
relationship. Continuous or extended infusion has been pro-
posed in almost all β-lactam modelling studies found in this 
review [21, 23–26, 28, 32, 35, 61] and is recommended in a 
recent guideline from the French Society of Anaesthesia and 
Intensive Care Medicine (SFAR) [97]. Additionally, clini-
cians can be supported by PK-PD software using a combi-
nation of PopPK models, Bayesian forecasting and TDM, 
to ensure optimal target attainment in special populations 
or individual patients. In the previously mentioned SFAR 
guideline the use of TDM is also recommend, including an 
overview of suggested PD targets for several β-lactam anti-
biotics [97]. However, although several software packages 
are available [5], successful clinical implementation requires 
close collaboration between clinicians and pharmacists. 
Additionally, it is still unknown whether optimizing target 
attainment of antibiotics will result in a clinical benefit in 
terms of survival or duration of ICU-stay. Although several 
meta-analyses and large clinical studies show contradicting 
evidence in adults [98–103], 1 smaller study showed a low 
mortality of only 4.2% in a selective pediatric sepsis cohort 
when TDM and non-standard dosing was applied, even after 
initial subtherapeutic antibiotic concentrations [3]. Ideally, 
large clinical trials aiming to identify whether this increased 
target attainment of antibiotics leads to a reduced morbidity 
and/or mortality should be conducted in both critically ill 
adult and pediatric patients.
5  Conclusion
This systematic review shows that the PK of most antibiotics 
is significantly altered during critical illness in children. For 
most drugs both Vd and Cl are increased, putting this popu-
lation at increased risk for suboptimal target attainment. A 
second main finding in this review is the lack of knowledge 
of PK in critically ill children of several, frequently used 
antibiotic agents such as ceftriaxone, ceftazidime, penicil-
lin, flucloxacillin and metronidazole. Finally, the majority 
of articles do not provide any dosing guidance for PICU 
patients, even if the necessary PK-parameters to simulate 
dosing regimens are presented in the paper.
Adequate antibiotic dosing of critically ill children 
is challenging, due to a wide range pathophysiological 
changes, developmental differences between different age 
groups and great within and between subject variability in 
PK. This challenging landscape requires close collaboration 
between clinicians, pharmacists and clinical pharmacolo-
gists, as expertise of all these parties is required for an accu-
rate assessment of this patient population. This literature 
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overview hopes to inspire both researchers and clinicians in 
this field to close these gaps, not only by presenting pharma-
cokinetic data, but also by providing guidance for implemen-
tation in the clinic, as this information is vital to optimize 
antibiotic treatment in this vulnerable population.
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